Dergiler / PressAcademia Procedia / 2017 / Cilt: 5 - Sayı: 1

BUDESONIDE SELF-NANOEMULSION FORMULATION AS AN ORAL DRUG DELIVERY SYSTEM: PREPARATION, CHARACTERIZATION AND CYTOTOXICITY STUDIES

Sayfa
41–46
Yayın Tarihi
2017-06-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The aim of this study was to increase solubility of Budesonide by using new Snedds formulation approach.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Lipophilic drugs which are poorly water soluble need specific applications like lipid based delivery systems to increase their oral absorption across gastrointestinal tract.
📊
Temel Bulgular & Veri:Selfnanoemulsifying drug delivery systems are Lipid Based Drug Delivery systems (SNEEDs) and are consists of an isotropic mixture of oil, surfactant(s) and co-surfactant.
💡
Sonuç & Katkı:The aim of this study was to increase solubility of Budesonide by using new Snedds formulation approach.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Budesonide · self-nanoemulsion drug delivery · oral drug delivery

Abstract

Lipophilic drugs which are poorly water soluble need specific applications like lipid based delivery systems to increase their oral absorption across gastrointestinal tract. Selfnanoemulsifying drug delivery systems are Lipid Based Drug Delivery systems (SNEEDs) and are consists of an isotropic mixture of oil, surfactant(s) and co-surfactant. This drug delivery systems are prepared at room temperature with gentle stirring process without using any other component or heating process and become nanoemulsion form upon gentle agitation in aqueous phase. SNEDDs have many advantages such as they can be produced easily and they are affected less from other outside factors, its scaleup process is easy, unaffected by lipid digestion, carry and protect peptides which can be enzymatically hydrolyzed. The aim of this study was to increase solubility of Budesonide by using new Snedds formulation approach.

🔖

Bu Makaleye Atıf Yap

Mesut, B., Sahin, S. H. T., Ozsoy, Y. (2017). BUDESONIDE SELF-NANOEMULSION FORMULATION AS AN ORAL DRUG DELIVERY SYSTEM: PREPARATION, CHARACTERIZATION AND CYTOTOXICITY STUDIES. PressAcademia Procedia, Cilt: 5 - Sayı: 1, 41–46. https://ajindex.com/articles/842561

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Ali, H. S., York, P., Blagden, N., Soltanpour, S., Acree Jr., W. E., Jouyban, A. 2010. “Solubility of budesonide, hydrocortisone, and prednisolone in ethanol + water mixtures at 298.2 K,”, Journal of Chemical and Engineering Data, vol. 55(1), pp. 578–582.
  2. Amidon, G.L., Lennernäs, H., Shah, V.P., Crison, J.R. 1995. “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability”, Pharmaceutical Research, vol. 12, pp. 413–420.
  3. Balakumar, K., Raghavan, C.V., Selvan, N.T., Prasad, R.H., Abdu, S. 2013. “Self nanoemulsifying drug delivery system (SNEDDS) of Rosuvastatin calcium: Design, formulation, bioavailability and pharmacokinetic evaluation”. Colloids and Surfaces B: Biointerfaces, vol. 112, pp. 337–343.
  4. Bernkop-Schnürch, A. 2013, “Nanocarrier systems for oral drug delivery: Dowereally need them?”. European Journal of Pharmaceutical Sciences, vol. 49, pp. 272–277.
  5. Bua, P., Narayanana, S., Dalrymplec, D., Chenga, X., Serajuddin A.T.M. 2016, “Cytotoxicity assessment of lipid-based self-emulsifying drug delivery system with Caco-2 cell model: Cremophor EL as the surfactant”, European Journal of Pharmaceutical Sciences, vol. 91, pp. 162– 171. Ek, A., Larsson, K., Siljerud, S., Palmberg, L. 1999. “Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages”, Allergy, vol. 54, pp. 691–699.
  6. Fotakis, G., Timbrell, J.A. 2006. “In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride”, Toxicol Lett., vol. 160(2), pp. 171-177. http://www.marketsandmarkets.com/Market-Reports/north-american-drug-delivery-technologies-market-1209.html, Accessed on 17.03.2017 http://www.marketsandmarkets.com/Market-Reports/north-american-drug-delivery-technologies-market-1209.html, Accessed on 17.03.2017
  7. Hvizdos, K.M., Jarvis, B, 2000. “Budesonide inhalation suspension: a review of its inflammatory respiratory disorders”, Drugs, vol. 60 (5), pp.1141–1178. Janković, J., Djekic, L., Dobričićc, V., Primoracb. 2016. “Evaluation of critical formulation parameters in design and differentiation of selfmicroemulsifying drug delivery systems (SMEDDSs) for oral delivery of acyclovir”, International Journal of Pharmacy, vol. 497(1–2), pp. 301–311.
  8. Meloche, C.A., Sharma, V., Swedmark, S., Andersson, P., Falany, C.N. 2002. “Sulfation of budesonide by human cytosolic sulfotransferase, de